IPP Bureau
Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
By IPP Bureau - December 20, 2022
Allam was serving recently as the CEO at Public Investment Fund
Ipca acquires further 6.53% of equity share of Trophic Wellness
By IPP Bureau - December 20, 2022
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Emcure conducts oral and health check-up camps for students in Pune
By IPP Bureau - December 20, 2022
The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors
Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules
By IPP Bureau - December 20, 2022
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
USFDA inspection at Alembic Pharmaceuticals’ facility at Jarod
By IPP Bureau - December 20, 2022
None of the observations are related to data integrity and management believes that they are addressable
Enhertu to demonstrate a significant survival benefit vs. chemotherapy
By IPP Bureau - December 20, 2022
Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
By IPP Bureau - December 20, 2022
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Guerison to set up footprints in India’s ophthalmology market
By IPP Bureau - December 20, 2022
Global pharmaceutical company having a surgical business concept incepted in Dubai
Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
By IPP Bureau - December 20, 2022
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
By IPP Bureau - December 20, 2022
Positive opinions based on significant survival benefit
4.4 crore health records of citizens digitized and linked with ABHA
By IPP Bureau - December 20, 2022
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
By IPP Bureau - December 20, 2022
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
SRL Diagnostics launches laboratory in Panchkula
By IPP Bureau - December 19, 2022
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet
By IPP Bureau - December 19, 2022
The product is backed by required scientific proof and comparative bioequivalence studies
